These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 11499697)

  • 21. Dendritic Cell-Based Cancer Vaccines.
    Santos PM; Butterfield LH
    J Immunol; 2018 Jan; 200(2):443-449. PubMed ID: 29311386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines.
    Schnurr M; Galambos P; Scholz C; Then F; Dauer M; Endres S; Eigler A
    Cancer Res; 2001 Sep; 61(17):6445-50. PubMed ID: 11522639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
    Seledtsov VI; Goncharov AG; Seledtsova GV
    Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cancer immunotherapy by fusions of dendritic cells and tumor cells.
    Koido S; Hara E; Homma S; Ohkusa T; Gong J; Tajiri H
    Immunotherapy; 2009 Jan; 1(1):49-62. PubMed ID: 20635973
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The present status and future prospects of peptide-based cancer vaccines.
    Hirayama M; Nishimura Y
    Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor cell lysates as immunogenic sources for cancer vaccine design.
    González FE; Gleisner A; Falcón-Beas F; Osorio F; López MN; Salazar-Onfray F
    Hum Vaccin Immunother; 2014; 10(11):3261-9. PubMed ID: 25625929
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dendritic cell vaccines for cancer immunotherapy.
    Timmerman JM; Levy R
    Annu Rev Med; 1999; 50():507-29. PubMed ID: 10073291
    [TBL] [Abstract][Full Text] [Related]  

  • 29. T cells as vehicles for cancer vaccination.
    Bear AS; Cruz CR; Foster AE
    J Biomed Biotechnol; 2011; 2011():417403. PubMed ID: 22131805
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors.
    Kamigaki T; Kaneko T; Naitoh K; Takahara M; Kondo T; Ibe H; Matsuda E; Maekawa R; Goto S
    Anticancer Res; 2013 Jul; 33(7):2971-6. PubMed ID: 23780988
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients.
    de Vries IJ; Lesterhuis WJ; Scharenborg NM; Engelen LP; Ruiter DJ; Gerritsen MJ; Croockewit S; Britten CM; Torensma R; Adema GJ; Figdor CG; Punt CJ
    Clin Cancer Res; 2003 Nov; 9(14):5091-100. PubMed ID: 14613986
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhanced stimulation of anti-breast cancer T cells responses by dendritic cells loaded with poly lactic-co-glycolic acid (PLGA) nanoparticle encapsulated tumor antigens.
    Iranpour S; Nejati V; Delirezh N; Biparva P; Shirian S
    J Exp Clin Cancer Res; 2016 Oct; 35(1):168. PubMed ID: 27782834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibitory effect of RNA pool complexity on stimulatory capacity of RNA-pulsed dendritic cells.
    Javorovic M; Wilde S; Zobywalski A; Noessner E; Lennerz V; Wölfel T; Schendel DJ
    J Immunother; 2008 Jan; 31(1):52-62. PubMed ID: 18157012
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antigen-specific vaccines for cancer treatment.
    Tagliamonte M; Petrizzo A; Tornesello ML; Buonaguro FM; Buonaguro L
    Hum Vaccin Immunother; 2014; 10(11):3332-46. PubMed ID: 25483639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. mRNA Cancer Vaccines.
    Fiedler K; Lazzaro S; Lutz J; Rauch S; Heidenreich R
    Recent Results Cancer Res; 2016; 209():61-85. PubMed ID: 28101688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Building on dendritic cell subsets to improve cancer vaccines.
    Palucka K; Ueno H; Zurawski G; Fay J; Banchereau J
    Curr Opin Immunol; 2010 Apr; 22(2):258-63. PubMed ID: 20226644
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen.
    Wiethe C; Dittmar K; Doan T; Lindenmaier W; Tindle R
    J Immunol; 2003 Mar; 170(6):2912-22. PubMed ID: 12626542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors.
    Osada T; Nagaoka K; Takahara M; Yang XY; Liu CX; Guo H; Roy Choudhury K; Hobeika A; Hartman Z; Morse MA; Lyerly HK
    J Immunother; 2015 May; 38(4):155-64. PubMed ID: 25839441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dendritic cell-based immunotherapy.
    Osada T; Clay TM; Woo CY; Morse MA; Lyerly HK
    Int Rev Immunol; 2006; 25(5-6):377-413. PubMed ID: 17169781
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
    Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
    Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.